Cargando…

Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate

To identify the clinical factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis, we examined 312 patients (253 females, 59 males) with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology. All patients included in this analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Majorczyk, Edyta, Mazurek-Mochol, Małgorzata, Pawlik, Andrzej, Kuśnierczyk, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605160/
https://www.ncbi.nlm.nih.gov/pubmed/36294398
http://dx.doi.org/10.3390/jcm11206078
_version_ 1784817996203556864
author Majorczyk, Edyta
Mazurek-Mochol, Małgorzata
Pawlik, Andrzej
Kuśnierczyk, Piotr
author_facet Majorczyk, Edyta
Mazurek-Mochol, Małgorzata
Pawlik, Andrzej
Kuśnierczyk, Piotr
author_sort Majorczyk, Edyta
collection PubMed
description To identify the clinical factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis, we examined 312 patients (253 females, 59 males) with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology. All patients included in this analysis began treatment with a regimen of oral MTX 7.5 mg weekly, with the dosage increasing to 15 mg weekly after 4 weeks, in combination with folic acid (1 mg daily). Good responders were defined as patients who had a DAS28 of ≤2.4 at 6 months (patients with remission of disease symptoms). Poor responders were defined as patients who had a DAS28 of >2.4. In this study, we analyzed the association between clinical parameters such as sex of patients, age of patients, age at disease onset, disease duration, rheumatoid factor, anti-CCP antibodies, ESR values, presence of joints erosions, presence of extra-articular manifestations and the response to MTX in RA patients. Multivariate logistic regression analysis showed four independent factors significantly associated with good response to MTX treatment: older age at disease onset, low ESR, no erosive disease and negative RF. The results of our study suggest that a younger age at disease onset, the presence of RF, erosive disease, as well as a high level of ESR are associated with worse response to MTX therapy.
format Online
Article
Text
id pubmed-9605160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96051602022-10-27 Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate Majorczyk, Edyta Mazurek-Mochol, Małgorzata Pawlik, Andrzej Kuśnierczyk, Piotr J Clin Med Article To identify the clinical factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis, we examined 312 patients (253 females, 59 males) with rheumatoid arthritis diagnosed according to the criteria of the American College of Rheumatology. All patients included in this analysis began treatment with a regimen of oral MTX 7.5 mg weekly, with the dosage increasing to 15 mg weekly after 4 weeks, in combination with folic acid (1 mg daily). Good responders were defined as patients who had a DAS28 of ≤2.4 at 6 months (patients with remission of disease symptoms). Poor responders were defined as patients who had a DAS28 of >2.4. In this study, we analyzed the association between clinical parameters such as sex of patients, age of patients, age at disease onset, disease duration, rheumatoid factor, anti-CCP antibodies, ESR values, presence of joints erosions, presence of extra-articular manifestations and the response to MTX in RA patients. Multivariate logistic regression analysis showed four independent factors significantly associated with good response to MTX treatment: older age at disease onset, low ESR, no erosive disease and negative RF. The results of our study suggest that a younger age at disease onset, the presence of RF, erosive disease, as well as a high level of ESR are associated with worse response to MTX therapy. MDPI 2022-10-14 /pmc/articles/PMC9605160/ /pubmed/36294398 http://dx.doi.org/10.3390/jcm11206078 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Majorczyk, Edyta
Mazurek-Mochol, Małgorzata
Pawlik, Andrzej
Kuśnierczyk, Piotr
Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title_full Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title_fullStr Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title_full_unstemmed Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title_short Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
title_sort clinical factors and the outcome of treatment with methotrexate in rheumatoid arthritis: role of rheumatoid factor, erosive disease and high level of erythrocyte sedimentation rate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605160/
https://www.ncbi.nlm.nih.gov/pubmed/36294398
http://dx.doi.org/10.3390/jcm11206078
work_keys_str_mv AT majorczykedyta clinicalfactorsandtheoutcomeoftreatmentwithmethotrexateinrheumatoidarthritisroleofrheumatoidfactorerosivediseaseandhighleveloferythrocytesedimentationrate
AT mazurekmocholmałgorzata clinicalfactorsandtheoutcomeoftreatmentwithmethotrexateinrheumatoidarthritisroleofrheumatoidfactorerosivediseaseandhighleveloferythrocytesedimentationrate
AT pawlikandrzej clinicalfactorsandtheoutcomeoftreatmentwithmethotrexateinrheumatoidarthritisroleofrheumatoidfactorerosivediseaseandhighleveloferythrocytesedimentationrate
AT kusnierczykpiotr clinicalfactorsandtheoutcomeoftreatmentwithmethotrexateinrheumatoidarthritisroleofrheumatoidfactorerosivediseaseandhighleveloferythrocytesedimentationrate